Skip to main content
Chongqing Pharscin Pharmaceutical Co., Ltd. logo

Chongqing Pharscin Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002907 ISIN · CNE100003308 LEI · 300300M2F5XMGFAYMA24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2025-10-28 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002907

About Chongqing Pharscin Pharmaceutical Co., Ltd.

https://www.pharscin.com

Chongqing Pharscin Pharmaceutical Co., Ltd. is an integrated enterprise specializing in the research, development, production, and commercialization of chemical drugs and modern traditional Chinese medicine. The company focuses on therapeutic areas such as digestive system health, cardiovascular and cerebrovascular diseases, and hepatobiliary conditions. Its portfolio includes a variety of proprietary formulations and generic medications, notably treatments for chronic liver disease and gastrointestinal disorders. Pharscin maintains advanced manufacturing facilities and a dedicated R&D infrastructure focused on enhancing drug efficacy and delivery systems. The organization emphasizes clinical value and technological innovation to provide comprehensive healthcare solutions across diverse medical sectors.

Recent filings

Filing Released Lang Actions
2025年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2025 年第三季度报告" which translates to "2025 Third Quarter Report". It contains detailed financial data including income statement, balance sheet, cash flow statement, and explanations of financial performance for the third quarter of 2025. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the period. It also mentions that the report is unaudited, which is typical for interim or quarterly reports. The length of the document (over 13,000 characters) and the detailed financial data confirm it is the actual report, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2025
2025-10-28 Chinese
关于公司获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Chongqing Huashen Pharmaceutical Co., Ltd. regarding the receipt of a drug registration certificate for their product Crizotinib Capsules. It includes details about the drug, regulatory approval by the National Medical Products Administration, and the impact on the company. The document is relatively short (1610 characters) and serves as a formal notification of regulatory approval rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or other report content. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-10-20 Chinese
关于公司控股股东一致行动人减持股份的预披露公告
Director's Dealing Classification · 95% confidence The document is a public announcement regarding the planned reduction of shareholdings by the company's controlling shareholders and their concerted actors. It details the shareholders involved, the number and percentage of shares to be reduced, the methods and timing of the reduction, and compliance with relevant securities regulations. There is no financial data, earnings information, or report content. The document is a formal disclosure of insider share transactions, specifically the planned share reduction by directors and major shareholders. This fits the definition of 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is 4445 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the correct classification is DIRS with high confidence.
2025-10-14 Chinese
关于公司收到药品再注册批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Chongqing Huashen Pharmaceutical Co., Ltd. regarding the receipt of drug re-registration approval notices from the Chongqing Drug Administration. It details the approval of re-registration for a chemical raw material drug and a pharmaceutical product, including registration numbers, approval validity, and product information. The document emphasizes compliance and the impact on production and sales but does not contain financial statements or detailed financial performance data. It is a regulatory announcement about drug approval status rather than a financial report or management discussion. The document length is short (1729 characters), and it serves as an official notification of regulatory approval. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-09-29 Chinese
关于公司收到药品再注册批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Chongqing Huashen Pharmaceutical Co., Ltd. regarding the receipt of drug re-registration approval notices from the Chongqing Drug Administration. It details the approval of chemical raw material drugs and drugs for injection, including registration numbers, approval validity, and product indications. The document emphasizes compliance and the impact on the company but does not contain financial data, management discussion, or detailed financial statements. It is a regulatory announcement about approvals and compliance rather than a financial report or management update. The document length is short (1785 characters) and is clearly an announcement of regulatory approval notices. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-09-24 Chinese
关于参加重庆辖区上市公司2025年投资者网上集体接待日暨半年度业绩说明会的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an investor online collective reception day and a semi-annual performance briefing event. It mentions the date and time of the event and invites investors to join an online platform for interaction with company executives. The document does not contain actual financial statements or detailed financial analysis but rather informs about an upcoming investor communication event. The document length is short (534 characters), and it serves as a notice rather than a report or transcript. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about investor relations activities and does not qualify as a Call Transcript (CT) or Interim Report (IR).
2025-09-18 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.